Adeona expands and enhances zinc-based product applicant portfolio Adeona Pharmaceuticals.

Adeona expands and enhances zinc-based product applicant portfolio Adeona Pharmaceuticals, Inc. , a developer of innovative medicines for serious central nervous system illnesses, announced today that it provides acquired access to clinical data supporting a zinc-structured therapy for preventing infections in older people . This acquisition expands and enhances Adeona’s zinc-based item candidate portfolio that already contains its proprietary zinc-centered tablets for use in the dietary administration of gentle to moderate Alzheimer’s disease and moderate cognitive impairment patients, and age-related macular degeneration.

Serious and/or serious attacks were reported in 6.2 percent of patients on belimumab and 6.3 percent of individuals on placebo. Significant and/or serious infusion reactions had been reported in 1.6 percent of individuals on belimumab and 0.3 percent of sufferers on placebo. Discontinuations because of adverse events were 5.4 percent in the belimumab treatment groups and 6.6 percent in the placebo treatment group. No malignancies had been reported. A complete of 9 deaths were reported in the analysis: 4, 2, and 3 in the belimumab 10 mg/kg, belimumab 1 mg/kg and placebo organizations, respectively.. Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010 Human Genome Sciences, Inc. The excess data will be presented in Rome at the 2010 Congress of the European Little league against Rheumatism on Saturday, 19 June.